» Articles » PMID: 33043516

Cancer Biology Functional Genomics: From Small RNAs to Big Dreams

Overview
Journal Mol Carcinog
Date 2020 Oct 12
PMID 33043516
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The year 2021 marks the 20th anniversary of the first publications reporting the discovery of the gene silencing mechanism, RNA interference (RNAi) in mammalian cells. Along with the many studies that delineated the proteins and substrates that form the RNAi pathway, this finding changed our understanding of the posttranscriptional regulation of mammalian gene expression. Furthermore, the development of methods that exploited the RNAi pathway began the technological revolution that eventually enabled the interrogation of mammalian gene function-from a single gene to the whole genome-in only a few days. The needs of the cancer research community have driven much of this progress. In this perspective, we highlight milestones in the development and application of RNAi-based methods to study carcinogenesis. We discuss how RNAi-based functional genetic analysis of exemplar tumor suppressors and oncogenes furthered our understanding of cancer initiation and progression and explore how such studies formed the basis of genome-wide scale efforts to identify cancer or cancer-type specific vulnerabilities, including studies conducted in vivo. Furthermore, we examine how RNAi technologies have revealed new cancer-relevant molecular targets and the implications for cancer of the first RNAi-based drugs. Finally, we discuss the future of functional genetic analysis, highlighting the increasing availability of complementary approaches to analyze cancer gene function.

Citing Articles

Uncovering hidden cancer self-dependencies through analysis of shRNA-level dependency scores.

Toghrayee Z, Montazeri H Sci Rep. 2024; 14(1):856.

PMID: 38195844 PMC: 10776685. DOI: 10.1038/s41598-024-51453-5.


Degradome-focused RNA interference screens to identify proteases important for breast cancer cell growth.

Holzen L, Syre K, Mitschke J, Brummer T, Miething C, Reinheckel T Front Oncol. 2022; 12:960109.

PMID: 36313646 PMC: 9598039. DOI: 10.3389/fonc.2022.960109.


Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug.

de Brito E Cunha D, Frederico A, Azamor T, Melgaco J, Neves P, Ano Bom A Pharmaceuticals (Basel). 2022; 15(5).

PMID: 35631401 PMC: 9146980. DOI: 10.3390/ph15050575.


RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System.

de Mey W, Esprit A, Thielemans K, Breckpot K, Franceschini L Clin Cancer Res. 2022; 28(18):3929-3939.

PMID: 35583609 PMC: 9475240. DOI: 10.1158/1078-0432.CCR-21-3304.


Cancer biology functional genomics: From small RNAs to big dreams.

Sundara Rajan S, Ludwig K, Hall K, Jones T, Caplen N Mol Carcinog. 2020; 59(12):1343-1361.

PMID: 33043516 PMC: 7702050. DOI: 10.1002/mc.23260.

References
1.
Prieur A, Tirode F, Cohen P, Delattre O . EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol. 2004; 24(16):7275-83. PMC: 479730. DOI: 10.1128/MCB.24.16.7275-7283.2004. View

2.
Barata P, Sood A, Hong D . RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. Cancer Treat Rev. 2016; 50:35-47. DOI: 10.1016/j.ctrv.2016.08.004. View

3.
Ghandi M, Huang F, Jane-Valbuena J, Kryukov G, Lo C, McDonald 3rd E . Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019; 569(7757):503-508. PMC: 6697103. DOI: 10.1038/s41586-019-1186-3. View

4.
Ray K, Wright R, Kallend D, Koenig W, Leiter L, Raal F . Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020; 382(16):1507-1519. DOI: 10.1056/NEJMoa1912387. View

5.
Czauderna F, Fechtner M, Aygun H, Arnold W, Klippel A, Giese K . Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA. Nucleic Acids Res. 2003; 31(2):670-82. PMC: 140507. DOI: 10.1093/nar/gkg141. View